NASDAQ: FATEFate Therapeutics Inc Stock
$3.80-0.07 (-1.81%)
Updated Apr 26, 2024
FATE Price
$3.80
Fair Value Price
N/A
Market Cap
$377.10M
52 Week Low
$1.63
52 Week High
$8.83
P/E
-2.32x
P/B
1.02x
P/S
5.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$63.53M
Earnings
-$160.93M
Gross Margin
100%
Operating Margin
-253.3%
Profit Margin
-253.3%
Debt to Equity
0.37
Operating Cash Flow
-$132M
Beta
1.62
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FATE Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FATE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FATE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FATE is good value based on its book value relative to its share price (1.02x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FATE due diligence checks available for Premium users.
Be the first to know about important FATE news, forecast changes, insider trades & much more!
FATE News
Valuation
FATE fair value
Fair Value of FATE stock based on Discounted Cash Flow (DCF)
Price
$3.80
Fair Value
-$0.03
Undervalued by
12,853.88%
FATE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FATE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.32x
Industry
14.88x
Market
41.14x
FATE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
5.85x
FATE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FATE's financial health
Profit margin
Revenue
$1.7M
Net Income
-$44.1M
Profit Margin
-2,632.6%
FATE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FATE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$506.2M
Liabilities
$137.8M
Debt to equity
0.37
FATE's short-term assets ($331.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FATE's short-term assets ($331.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FATE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FATE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.6M
Investing
$45.4M
Financing
-$180.0k
FATE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FATE vs Biotech Stocks
Fate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.